# US 2015/0174111 A1 · Insulin independence among patients with diabetes utilizing a ppi in combination with an immune tolerance agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0174111 A1
- Document ID: US20150174111A1
- Status: Published application
- Kind: A1
- Application number: 14/641,143
- Filed: 2015-03-06
- Published: 2015-06-25
- Earliest claimed: 2013-02-15
- Inventors: Claresa Levetan
- Web page: https://patentgrep.com/patent/US20150174111A1

## CPC

- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 38/02: Peptides of undefined number of amino acids; Derivatives thereof
- A61K 38/13: Cyclosporins
- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- A61K 38/20: Interleukins [IL]
- A61K 38/212: {IFN-alpha}
- A61K 38/55: Protease inhibitors
- A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 39/04: Mycobacterium, e.g. Mycobacterium tuberculosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

To date, no immune tolerance agent or combination of immune tolerance agents has been able to sustain insulin-independence among type 1 diabetes patients. This patent provides methods and pharmaceutical compositions for providing insulin independence among newly diagnosed and existing type 1 diabetes. Methods include utilization of PPIs, which increase gastrin resulting in the transformation of human ductal tissue into insulin-secreting new beta cells, used in combination with an immune tolerance agent to protect the new insulin-producing beta cells generated by the PPI from immune destruction. Compositions and methods are provided for beta cell generation therapy comprising at least one member from a group of PPIs with formulations selected from immune tolerance agents, when used in combination result in insulin-independence among new and existing type 1 patients whom currently require insulin to sustain life. Compositions and methods are provided for insulin-independence among type 2 patients using PPIs when combined with therapeutic agents utilized for the treatment of type 2 diabetes.

## Claims

### Claim 1

A method of treating a condition that is associated with or is a risk factor for impaired glucose homeostasis in a subject selected from new onset type 1 and 2 diabetes, previously existing type 1 and 2 diabetes, latent autoimmune diabetes of adulthood (LADA), glutamic acid decarboxylase-65 autoimmunity, prediabetes, hyperglycemia, glucose intolerance, beta cell impairment or deficiency, insulin resistance, obesity, polycystic ovarian syndrome, nonalcoholic steatohepatitis, hyperlipidemia, and hypertriglyceridemia, comprising the step of:
administering an amount of a proton pump inhibitor to the subject that is effective for generating new beta cells in the pancreas of the subject and/or reducing or preventing symptoms of the condition.

### Claim 2 (depends on 1)

The method of claim 1, further comprising the step of administering an amount of an immune tolerance agent to the subject that is effective for protecting the new beta cells from destruction from the immune system and/or reducing or preventing symptoms of the condition.

### Claim 3 (depends on 1)

The method of claim 1, further comprising the step of administering an amount of at least one other beta regeneration agent that is effective for generating new beta cells in the pancreas of the subject and/or reducing or preventing symptoms of the condition.

### Claim 4 (depends on 2)

The method of claim 2, further comprising the step of administering an amount of at least one other beta regeneration agent that is effective for generating new beta cells in the pancreas of the subject and/or reducing or preventing symptoms of the condition.

### Claim 5 (depends on 1)

The method of claim 1, wherein the proton pump inhibitor is selected from Omeprazole, Lansoprazole, Dexlansoprazole, Esomeprazole, Pantoprazole, Rabeprazole, and Ilaprazole.

### Claim 6 (depends on 2)

The method of claim 2, wherein the immune tolerance agent is selected from Cyclosporine, hOKT3γ1, ChAglyCD3, Rapamycin, Tacrolimus, Etanercept, Alefacept, Belatacept, Diapep277, a tuberculosis vaccine, Glutamic Acid Decarboxylase 65 (GAD65) vaccine; Bacillus Calmette-Guérin Vaccine, Mycophenolate Mofetil alone or in combination with Daclizumab; Rituximab; Campath-1H, lysofylline; antithymocyte globulin, Proleukin and the combination of Proleukin and Rapamune, Vitamin D, IBC-VSO vaccine, Ex vivo Expanded Human Autologous CD4+CD127lo/−CD25+ Polyclonal Regulatory T Cells; interferon-alpha; a vaccine using CD4+CD25+ antigen-specific regulatory T cells, Interleukin-1 Receptor Antagonist (anakinra), and Alpha 1-Antitrypsin.

### Claim 7 (depends on 3)

The method of claim 3, wherein the other beta regeneration agent is a Reg Peptide, or a formulation, derivative, optimized form or peptidomimetic of a Reg Peptide.

### Claim 8 (depends on 4)

The method of claim 4, wherein the other beta regeneration agent is a Reg Peptide, or a formulation, derivative, optimized form or peptidomimetic of a Reg Peptide.

### Claim 9 (depends on 2)

The method of claim 2, wherein the proton pump inhibitor is Lansoprazole.

### Claim 10 (depends on 2)

The method of claim 2, wherein the immune tolerance agent is Cyclosporine.

### Claim 11 (depends on 2)

The method of claim 2, wherein the proton pump inhibitor and the immune tolerance agent are formulated together in a pharmaceutical composition.

### Claim 12 (depends on 11)

The method of claim 11, wherein the proton pump inhibitor is Lansoprazole.

### Claim 13 (depends on 11)

The method of claim 11, wherein the immune tolerance agent is Cyclosporine.

### Claim 14 (depends on 11)

The method of claim 11, wherein the proton pump inhibitor is Lansoprazole and the immune tolerance agent is Cyclosporine.

### Claim 15 (depends on 14)

The method of claim 14, wherein Lansoprazole and Cyclosporine are formulated together in a capsule, pill, suspension, or solution.

### Claim 16

A method for treating a pathology associated specifically with impaired pancreatic function in a subject comprising the step of:
administering a therapeutically effective amount of a proton pump inhibitor to the subject.

### Claim 17 (depends on 16)

The method of claim 16, further comprising the step of administering a therapeutically effective amount of an immune tolerance agent to the subject.

### Claim 18 (depends on 17)

The method of claim 17, further comprising one or more steps of:
(a) intensifying glycemic control;
(b) administering oral vitamin D to maintain 25-hydroxyvitamin levels above 40 mg/ml;
(c) reducing, or tapering off of other diabetes therapies as new beta cell populations are restored;
(d) lowering the dosage of the immune tolerance agent and the PPI as dosages of other diabetes medication, including insulin, are tapered off; and
(e) administering the lowest dosage formulations of PPIs alone and in combination with immune tolerance agents at intervals to maintain a minimum number of beta cells for normal glucose metabolism.

### Claim 19 (depends on 18)

The method of claim 18, wherein the pathology associated specifically with impaired pancreatic function is type 1 diabetes.

### Claim 20

A method of treating recent and existing type 1 diabetes in a subject comprising the step of administering Cyclosporine and another diabetes agent.
